Drug Price Trends for NDC 00904-7209

Average Pharmacy Cost for 00904-7209

Drug Name	NDC	Price/Unit ($)	Unit	Date
SEVELAMER HCL 800 MG TABLET	00904-7209-06	1.29093	EACH	2025-02-26

Best Wholesale Price for NDC 00904-7209

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
No data available in table

00904-7209 Market Analysis and Financial Projection

Here is an analysis of the market and price projections for the drug with NDC 00904-7209:

Key details:

• NDC 00904-7209 is for sevelamer hydrochloride tablets manufactured by Major Pharmaceuticals
• Sevelamer hydrochloride is a phosphate binder used to treat high phosphorus levels in patients with chronic kidney disease on dialysis

Market analysis:

• The global phosphate binder market was valued at $2.3 billion in 2022 and is projected to reach $3.5 billion by 2030, growing at a CAGR of 5.4% from 2023 to 2030[1].

• Key drivers of growth include increasing prevalence of chronic kidney disease and end-stage renal disease requiring dialysis.

• Sevelamer is one of the leading phosphate binders, with a significant market share. However, it faces competition from newer agents like sucroferric oxyhydroxide.

• Major manufacturers of sevelamer include Genzyme/Sanofi, Aurobindo, and Cipla, in addition to generic manufacturers like Major Pharmaceuticals.

Price projections:

• As a generic medication, sevelamer hydrochloride pricing has declined significantly since brand name Renagel lost patent protection.

• The average wholesale price (AWP) for sevelamer hydrochloride 800 mg tablets was around $6-7 per tablet in 2022[2].

• Prices are expected to remain relatively stable, with potential for modest decreases of 1-3% annually as additional generic competition enters the market.

• However, increasing demand may help offset downward pricing pressure to some degree.

• Reimbursement rates from Medicare and private insurers will be a key factor influencing pricing. Any significant changes to reimbursement policy could impact market dynamics.

• Overall, pricing is projected to decline gradually at 1-3% per year over the next 3-5 years, barring any major regulatory or competitive changes in the phosphate binder market.

In summary, sevelamer hydrochloride remains an important treatment option in a growing market, but as a mature generic product it faces ongoing pricing pressure. Modest price declines are expected in the coming years as the phosphate binder market becomes increasingly competitive.

References:

1. Phosphate Binders Market Size & Share Report, 2030. Grand View Research.
2. Red Book Online. Micromedex Solutions. Truven Health Analytics.